---
title: 'Safety and efficacy of dasotraline for patients with attention deficit/hyperactivity
  disorder: a systematic review and meta-analysis of 1594 patients including GRADE
  qualifications.**DOI:** 10.1007/s00213-024-06723-5'
authors:
- Mohamed Ezzat MMansour
- Khalid RadwanAlsaadany
- Mohamed Awad EAhmed
- Ahmed EzzatElmetwalli
journal: Psychopharmacology
doi: 10.1007/s00213-024-06723-5
publication_date: ''
source: Processed from scraped content
processing_date: '2025-10-21T22:15:05.848498'
content_type: research_paper
conditions:
- adhd
- asd
topics:
- neurochemistry
categories:
- adhd
- asd
- neurochemistry
reading_level: academic
audience:
- professional
- researcher
patient_friendly: false
search_priority: standard
keywords:
- clinical
- treatment
search_tags:
- asd
- adhd
- peer-reviewed
- academic
- research
- neurochemistry
---

# Safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including GRADE qualifications.**DOI:** 10.1007/s00213-024-06723-5

**Authors:** Mohamed Ezzat MMansour, Khalid RadwanAlsaadany, Mohamed Awad EAhmed, Ahmed EzzatElmetwalli

**Journal:** Psychopharmacology

**DOI:** 10.1007/s00213-024-06723-5

## Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder. It is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. This study aimed to create evidence from published randomized clinical trials (RCTs) about the benefits of dasotraline for ADHD patients.
A computer literature search (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) was conducted. We included RCTs comparing dasotraline versus placebo. The primary outcome measure was the ADHD Rating Scale-IV score, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcome measures were the ADHD Rating Scale-IV Inattention score, ADHD Rating Scale-IV Hyperactivity score.
Five RCTs with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (MD -2.65, 95% CI [-4.14 to -1.17], P= 0.0004 CONCLUSION: The results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for ADHD symptoms. However, mild to moderate side effects were observed.

A computer literature search (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) was conducted. We included RCTs comparing dasotraline versus placebo. The primary outcome measure was the ADHD Rating Scale-IV score, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcome measures were the ADHD Rating Scale-IV Inattention score, ADHD Rating Scale-IV Hyperactivity score.
Five RCTs with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (MD -2.65, 95% CI [-4.14 to -1.17], P= 0.0004 CONCLUSION: The results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for ADHD symptoms. However, mild to moderate side effects were observed.## Full Text## Abstract
introduction attention-deficit/hyperactivity disorder (adhd) is a complex neurodevelopmental disorder. it is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. this study aimed to create evidence from published randomized clinical trials (rcts) about the benefits of dasotraline for adhd patients. methods a computer literature search (pubmed, scopus, web of science, and cochrane central) was conducted. we included rcts comparing dasotraline versus placebo. the primary outcome measure was the adhd rating scale-iv score, pooled as the mean difference between the two groups from baseline to the endpoint. the secondary outcome measures were the adhd rating scale-iv inattention score, adhd rating scale-iv hyperactivity score. results five rcts with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (md –2.65, 95% ci [–4.14 to –1.17], p= 0.0004 conclusion the results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed. this is a preview of subscription content, log in via an institution to check access. access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } fig. 1 fig. 2 fig. 3 fig. 4 fig. 5 fig. 6 fig. 7 similar content being viewed by others nonstimulant medications for attention-deficit/hyperactivity disorder (adhd) in adults: systematic review and meta-analysis article 11 may 2023 pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults article open access 23 november 2015 efficacy of pharmacological interventions for adhd: protocol for an updated systematic review and dose–response network meta-analysis article open access 12 october 2024 window.datalayer = window.datalayer || []; window.datalayer.push({ recommendations: { recommender: 'semantic', model: 'specter', policy_id: 'na', timestamp: 1761044428, embedded_user: 'null' } }); explore related subjects discover the latest articles, books and news in related subjects, suggested using machine learning. adhd attention deficit disorder drug therapy drug screening parkinson's disease therapeutics references sapkale b, sawal a (2023) attention deficit hyperactivity disorder (adhd) causes and diagnosis in adults: a review. cureus 15(11):e49144 pubmed pubmed central google scholar vold jh, halmøy a, chalabianloo f, pierron mc, løberg e-m, johansson ka et al (2023) attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study. bmc psychiatry 23(1):479 article pubmed pubmed central cas google scholar scandurra v, emberti gialloreti l, barbanera f, scordo mr, pierini a, canitano r (2019) neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (asd) and/or attention deficit and hyperactivity disorder (adhd). front psychiatry 10:673 article pubmed pubmed central google scholar abdelnour e, jansen mo, gold ja (2022) adhd diagnostic trends: increased recognition or overdiagnosis? mo med 119(5):467–473 pubmed pubmed central google scholar li y, yan x, li q, li q, xu g, lu j et al (2023) prevalence and trends in diagnosed adhd among us children and adolescents, 2017–2022. jama netw open 6(10):e2336872 article pubmed pubmed central google scholar schein j, adler la, childress a, cloutier m, gagnon-sanschagrin p, davidson m et al (2022) economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the united states: a societal perspective. j med econ 25(1):193–205 article pubmed google scholar schein j, adler la, childress a, gagnon-sanschagrin p, davidson m, kinkead f et al (2022) economic burden of attention-deficit/hyperactivity disorder among adults in the united states: a societal perspective. j manag care spec pharm 28(2):168–179 pubmed google scholar balazs j, kereszteny a (2017) attention-deficit/hyperactivity disorder and suicide: a systematic review. world j psychiatry 7(1):44–59 article pubmed pubmed central google scholar kosheleff ar, mason o, jain r, koch j, rubin j (2023) functional impairments associated with adhd in adulthood and the impact of pharmacological treatment. j atten disord 27(7):669–697 article pubmed pubmed central google scholar adamou m, arif m, asherson p, aw t-c, bolea b, coghill d et al (2013) occupational issues of adults with adhd. bmc psychiatry 13:59 article pubmed pubmed central google scholar sharma a, couture j (2014) a review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (adhd). ann pharmacother 48(2):209–225 article pubmed google scholar saboory e, ghasemi m, mehranfard n (2020) norepinephrine, neurodevelopment and behavior. neurochem int 135:104706 article pubmed cas google scholar klein mo, battagello ds, cardoso ar, hauser dn, bittencourt jc, correa rg (2019) dopamine: functions, signaling, and association with neurological diseases. cell mol neurobiol 39(1):31–59 article pubmed google scholar functional roles of norepinephrine and dopamine in adhd [internet]. [cited 2024 apr 9]. https://www.medscape.org/viewarticle/523887 curatolo p, d’agati e, moavero r. the neurobiological basis of adhd. italian journal of pediatrics [internet]. 2010;36(1):79. available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3016271/ ‌ pliszka sr, mccracken jt, maas jw (1996) catecholamines in attention-deficit hyperactivity disorder: current perspectives. j am acad child adolesc psychiatry 35(3):264–272 article pubmed cas google scholar faraone sv (2018) the pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. neurosci biobehav rev 87:255–270 article pubmed pubmed central cas google scholar reddy ds (2013) current pharmacotherapy of attention deficit hyperactivity disorder. drugs today 49(10):647–665 article cas google scholar verghese c, abdijadid s (2023) methylphenidate [internet]. nih.gov. statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk482451/ ‌ martin d, le jk (2023) amphetamine [internet]. pubmed. treasure island (fl): statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk556103/ ‌ delorenzo c, lichenstein s, schaefer k, dunn j, marshall r, organisak l et al (2011) sep-225289 serotonin and dopamine transporter occupancy: a pet study. j nucl med 52(7):1150–1155 article pubmed google scholar schreiber r, campbell u, quinton ms, hardy lw, fang qk, lew r (2022) in vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. biomed pharmacother 153:113359 article pubmed cas google scholar hopkins sc, sunkaraneni s, skende e, hing j, passarell ja, loebel a et al (2016) pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. clin drug investig 36(2):137–146 article pubmed cas google scholar chen y-l, skende e, lin j, yi y, wang pl, wills s et al (2017) absorption, distribution, metabolism, and excretion of [14 c]-dasotraline in humans. pharmacol res perspect 5(1):e00281 article pubmed google scholar wigal s, tsai j, bates ja, sarma k, tortorich d, zhu h et al (2022) a randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with adhd. j atten disord 26(10):1357–1368 article pubmed google scholar findling rl, adler la, spencer tj, goldman r, hopkins sc, koblan ks et al (2019) dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. j child adolesc psychopharmacol 29(2):80–89 article pubmed cas google scholar koblan ks, hopkins sc, sarma k, jin f, goldman r, kollins sh et al (2015) dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. neuropsychopharmacology 40(12):2745–2752 article pubmed pubmed central cas google scholar mcelroy sl, hudson ji, grilo cm, guerdjikova ai, deng l, koblan ks et al (2020) efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. j clin psychiatry 81(5) halevy-yosef r, bachar e, shalev l, pollak y, enoch-levy a, gur e et al (2019) the complexity of the interaction between binge-eating and attention. plos one 14(4):e0215506 article pubmed pubmed central cas google scholar page m, mckenzie j, bossuyt p, boutron i, hoffmann t, mulrow cd et al (2021) the prisma 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71 article pubmed pubmed central google scholar cochrane handbook for systematic reviews of interventions | cochrane training [internet]. [cited 2024 apr 10]. https://training.cochrane.org/handbook/current rayyan – intelligent systematic review - rayyan [internet]. [cited 2024 apr 10]. https://www.rayyan.ai/ higgins jpt, altman dg, gøtzsche pc, jüni p, moher d, oxman ad et al (2011) the cochrane collaboration’s tool for assessing risk of bias in randomised trials. bmj 343:d5928 article pubmed pubmed central google scholar döpfner m, steinhausen h-c, coghill d, dalsgaard s, poole l, ralston sj et al (2006) cross-cultural reliability and validity of adhd assessed by the adhd rating scale in a pan-european study. eur child adolesc psychiatry 15(suppl 1):i46–55 article pubmed google scholar busner j, targum sd (2007) the clinical global impressions scale: applying a research tool in clinical practice. psychiatry (edgmont) 4(7):28–37 pubmed google scholar wigal sb, gupta s, guinta d, swanson jm (1998) reliability and validity of the skamp rating scale in a laboratory school setting. psychopharmacol bull 34(1):47–53 pubmed cas google scholar murray dw, bussing r, fernandez m, wei hou, garvan cw, swanson jm et al (2009) psychometric properties of teacher skamp ratings from a community sample. assessment 16(2):193–208 article pubmed google scholar wigal sb, wigal t, schuck s, brams m, williamson d, armstrong rb et al (2011) academic, behavioral, and cognitive effects of oros ® methylphenidate on older children with attention-deficit/hyperactivity disorder. j child adolesc psychopharmacol 21(2):121–131 article pubmed pubmed central cas google scholar altman dg, bland jm (2005) standard deviations and standard errors. bmj 331(7521):903 article pubmed pubmed central google scholar egger m, smith g, schneider m, minder c (1997) bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629–634 article pubmed pubmed central cas google scholar grade handbook [internet] [cited 2024 apr 10]. https://gdt.gradepro.org/app/handbook/handbook.html wigal sb, hopkins sc, koblan ks, childress a, kent jm, tsai j et al (2020) efficacy and safety of dasotraline in children with adhd: a laboratory classroom study. j atten disord 24(2):192–204 article pubmed google scholar adler la, goldman r, hopkins sc, koblan ks, kent j, hsu j et al (2021) dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. int clin psychopharmacol 36(3):117–125 article pubmed google scholar peasgood t, bhardwaj a, biggs k, brazier je, coghill d, cooper cl et al (2016) the impact of adhd on the health and well-being of adhd children and their siblings. eur child adolesc psychiatry 25(11):1217–1231 article pubmed pubmed central google scholar download references author information authors and affiliations faculty of medicine, zagazig university, zagazig, egypt mohamed ezzat m. mansour medical research group of egypt, negida academy, arlington, ma, usa mohamed ezzat m. mansour, khalid radwan alsaadany, mohamed awad e. ahmed & ahmed ezzat elmetwalli faculty of medicine, mansoura university, mansoura, egypt khalid radwan alsaadany faculty of medicine, suez university, suez, egypt mohamed awad e. ahmed faculty of medicine, misr university for science and technology, giza, egypt ahmed ezzat elmetwalli authors mohamed ezzat m. mansour view author publications search author on: pubmed google scholar khalid radwan alsaadany view author publications search author on: pubmed google scholar mohamed awad e. ahmed view author publications search author on: pubmed google scholar ahmed ezzat elmetwalli view author publications search author on: pubmed google scholar corresponding author correspondence to mohamed ezzat m. mansour . ethics declarations competing of interest the authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper. additional information publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. supplementary information below is the link to the electronic supplementary material. esm 1 (docx 2.50 mb) rights and permissions springer nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. reprints and permissions about this article cite this article mansour, m.e.m., alsaadany, k.r., ahmed, m.a.e. et al. safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications. psychopharmacology 242 , 45–62 (2025). https://doi.org/10.1007/s00213-024-06723-5 download citation received : 18 september 2024 accepted : 22 november 2024 published : 19 december 2024 issue date : january 2025 doi : https://doi.org/10.1007/s00213-024-06723-5 share this article anyone you share the following link with will be able to read this content: get shareable link sorry, a shareable link is not currently available for this article. copy shareable link to clipboard provided by the springer nature sharedit content-sharing initiative keywords attention deficit/hyperactivity adhd dasotraline dopamine norepinephrine access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['mpu1'] = { 'pos': 'mpu1', 'type': 'mpu1', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; search search by keyword or author search navigation find a journal publish with us track your research discover content journals a-z books a-z publish with us journal finder publish your research language editing open access publishing products and services our products librarians societies partners and advertisers our brands springer nature portfolio bmc palgrave macmillan apress discover your privacy choices/manage cookies your us state privacy rights accessibility statement terms and conditions privacy policy help and support legal notice cancel contracts here 54.203.101.43 not affiliated © 2025 springer nature## Introduction
attention-deficit/hyperactivity disorder (adhd) is a complex neurodevelopmental disorder. it is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. this study aimed to create evidence from published randomized clinical trials (rcts) about the benefits of dasotraline for adhd patients. methods a computer literature search (pubmed, scopus, web of science, and cochrane central) was conducted. we included rcts comparing dasotraline versus placebo. the primary outcome measure was the adhd rating scale-iv score, pooled as the mean difference between the two groups from baseline to the endpoint. the secondary outcome measures were the adhd rating scale-iv inattention score, adhd rating scale-iv hyperactivity score. results five rcts with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (md –2.65, 95% ci [–4.14 to –1.17], p= 0.0004 conclusion the results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed. this is a preview of subscription content, log in via an institution to check access. access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } fig. 1 fig. 2 fig. 3 fig. 4 fig. 5 fig. 6 fig. 7 similar content being viewed by others nonstimulant medications for attention-deficit/hyperactivity disorder (adhd) in adults: systematic review and meta-analysis article 11 may 2023 pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults article open access 23 november 2015 efficacy of pharmacological interventions for adhd: protocol for an updated systematic review and dose–response network meta-analysis article open access 12 october 2024 window.datalayer = window.datalayer || []; window.datalayer.push({ recommendations: { recommender: 'semantic', model: 'specter', policy_id: 'na', timestamp: 1761044428, embedded_user: 'null' } }); explore related subjects discover the latest articles, books and news in related subjects, suggested using machine learning. adhd attention deficit disorder drug therapy drug screening parkinson's disease therapeutics references sapkale b, sawal a (2023) attention deficit hyperactivity disorder (adhd) causes and diagnosis in adults: a review. cureus 15(11):e49144 pubmed pubmed central google scholar vold jh, halmøy a, chalabianloo f, pierron mc, løberg e-m, johansson ka et al (2023) attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study. bmc psychiatry 23(1):479 article pubmed pubmed central cas google scholar scandurra v, emberti gialloreti l, barbanera f, scordo mr, pierini a, canitano r (2019) neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (asd) and/or attention deficit and hyperactivity disorder (adhd). front psychiatry 10:673 article pubmed pubmed central google scholar abdelnour e, jansen mo, gold ja (2022) adhd diagnostic trends: increased recognition or overdiagnosis? mo med 119(5):467–473 pubmed pubmed central google scholar li y, yan x, li q, li q, xu g, lu j et al (2023) prevalence and trends in diagnosed adhd among us children and adolescents, 2017–2022. jama netw open 6(10):e2336872 article pubmed pubmed central google scholar schein j, adler la, childress a, cloutier m, gagnon-sanschagrin p, davidson m et al (2022) economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the united states: a societal perspective. j med econ 25(1):193–205 article pubmed google scholar schein j, adler la, childress a, gagnon-sanschagrin p, davidson m, kinkead f et al (2022) economic burden of attention-deficit/hyperactivity disorder among adults in the united states: a societal perspective. j manag care spec pharm 28(2):168–179 pubmed google scholar balazs j, kereszteny a (2017) attention-deficit/hyperactivity disorder and suicide: a systematic review. world j psychiatry 7(1):44–59 article pubmed pubmed central google scholar kosheleff ar, mason o, jain r, koch j, rubin j (2023) functional impairments associated with adhd in adulthood and the impact of pharmacological treatment. j atten disord 27(7):669–697 article pubmed pubmed central google scholar adamou m, arif m, asherson p, aw t-c, bolea b, coghill d et al (2013) occupational issues of adults with adhd. bmc psychiatry 13:59 article pubmed pubmed central google scholar sharma a, couture j (2014) a review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (adhd). ann pharmacother 48(2):209–225 article pubmed google scholar saboory e, ghasemi m, mehranfard n (2020) norepinephrine, neurodevelopment and behavior. neurochem int 135:104706 article pubmed cas google scholar klein mo, battagello ds, cardoso ar, hauser dn, bittencourt jc, correa rg (2019) dopamine: functions, signaling, and association with neurological diseases. cell mol neurobiol 39(1):31–59 article pubmed google scholar functional roles of norepinephrine and dopamine in adhd [internet]. [cited 2024 apr 9]. https://www.medscape.org/viewarticle/523887 curatolo p, d’agati e, moavero r. the neurobiological basis of adhd. italian journal of pediatrics [internet]. 2010;36(1):79. available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3016271/ ‌ pliszka sr, mccracken jt, maas jw (1996) catecholamines in attention-deficit hyperactivity disorder: current perspectives. j am acad child adolesc psychiatry 35(3):264–272 article pubmed cas google scholar faraone sv (2018) the pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. neurosci biobehav rev 87:255–270 article pubmed pubmed central cas google scholar reddy ds (2013) current pharmacotherapy of attention deficit hyperactivity disorder. drugs today 49(10):647–665 article cas google scholar verghese c, abdijadid s (2023) methylphenidate [internet]. nih.gov. statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk482451/ ‌ martin d, le jk (2023) amphetamine [internet]. pubmed. treasure island (fl): statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk556103/ ‌ delorenzo c, lichenstein s, schaefer k, dunn j, marshall r, organisak l et al (2011) sep-225289 serotonin and dopamine transporter occupancy: a pet study. j nucl med 52(7):1150–1155 article pubmed google scholar schreiber r, campbell u, quinton ms, hardy lw, fang qk, lew r (2022) in vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. biomed pharmacother 153:113359 article pubmed cas google scholar hopkins sc, sunkaraneni s, skende e, hing j, passarell ja, loebel a et al (2016) pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. clin drug investig 36(2):137–146 article pubmed cas google scholar chen y-l, skende e, lin j, yi y, wang pl, wills s et al (2017) absorption, distribution, metabolism, and excretion of [14 c]-dasotraline in humans. pharmacol res perspect 5(1):e00281 article pubmed google scholar wigal s, tsai j, bates ja, sarma k, tortorich d, zhu h et al (2022) a randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with adhd. j atten disord 26(10):1357–1368 article pubmed google scholar findling rl, adler la, spencer tj, goldman r, hopkins sc, koblan ks et al (2019) dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. j child adolesc psychopharmacol 29(2):80–89 article pubmed cas google scholar koblan ks, hopkins sc, sarma k, jin f, goldman r, kollins sh et al (2015) dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. neuropsychopharmacology 40(12):2745–2752 article pubmed pubmed central cas google scholar mcelroy sl, hudson ji, grilo cm, guerdjikova ai, deng l, koblan ks et al (2020) efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. j clin psychiatry 81(5) halevy-yosef r, bachar e, shalev l, pollak y, enoch-levy a, gur e et al (2019) the complexity of the interaction between binge-eating and attention. plos one 14(4):e0215506 article pubmed pubmed central cas google scholar page m, mckenzie j, bossuyt p, boutron i, hoffmann t, mulrow cd et al (2021) the prisma 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71 article pubmed pubmed central google scholar cochrane handbook for systematic reviews of interventions | cochrane training [internet]. [cited 2024 apr 10]. https://training.cochrane.org/handbook/current rayyan – intelligent systematic review - rayyan [internet]. [cited 2024 apr 10]. https://www.rayyan.ai/ higgins jpt, altman dg, gøtzsche pc, jüni p, moher d, oxman ad et al (2011) the cochrane collaboration’s tool for assessing risk of bias in randomised trials. bmj 343:d5928 article pubmed pubmed central google scholar döpfner m, steinhausen h-c, coghill d, dalsgaard s, poole l, ralston sj et al (2006) cross-cultural reliability and validity of adhd assessed by the adhd rating scale in a pan-european study. eur child adolesc psychiatry 15(suppl 1):i46–55 article pubmed google scholar busner j, targum sd (2007) the clinical global impressions scale: applying a research tool in clinical practice. psychiatry (edgmont) 4(7):28–37 pubmed google scholar wigal sb, gupta s, guinta d, swanson jm (1998) reliability and validity of the skamp rating scale in a laboratory school setting. psychopharmacol bull 34(1):47–53 pubmed cas google scholar murray dw, bussing r, fernandez m, wei hou, garvan cw, swanson jm et al (2009) psychometric properties of teacher skamp ratings from a community sample. assessment 16(2):193–208 article pubmed google scholar wigal sb, wigal t, schuck s, brams m, williamson d, armstrong rb et al (2011) academic, behavioral, and cognitive effects of oros ® methylphenidate on older children with attention-deficit/hyperactivity disorder. j child adolesc psychopharmacol 21(2):121–131 article pubmed pubmed central cas google scholar altman dg, bland jm (2005) standard deviations and standard errors. bmj 331(7521):903 article pubmed pubmed central google scholar egger m, smith g, schneider m, minder c (1997) bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629–634 article pubmed pubmed central cas google scholar grade handbook [internet] [cited 2024 apr 10]. https://gdt.gradepro.org/app/handbook/handbook.html wigal sb, hopkins sc, koblan ks, childress a, kent jm, tsai j et al (2020) efficacy and safety of dasotraline in children with adhd: a laboratory classroom study. j atten disord 24(2):192–204 article pubmed google scholar adler la, goldman r, hopkins sc, koblan ks, kent j, hsu j et al (2021) dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. int clin psychopharmacol 36(3):117–125 article pubmed google scholar peasgood t, bhardwaj a, biggs k, brazier je, coghill d, cooper cl et al (2016) the impact of adhd on the health and well-being of adhd children and their siblings. eur child adolesc psychiatry 25(11):1217–1231 article pubmed pubmed central google scholar download references author information authors and affiliations faculty of medicine, zagazig university, zagazig, egypt mohamed ezzat m. mansour medical research group of egypt, negida academy, arlington, ma, usa mohamed ezzat m. mansour, khalid radwan alsaadany, mohamed awad e. ahmed & ahmed ezzat elmetwalli faculty of medicine, mansoura university, mansoura, egypt khalid radwan alsaadany faculty of medicine, suez university, suez, egypt mohamed awad e. ahmed faculty of medicine, misr university for science and technology, giza, egypt ahmed ezzat elmetwalli authors mohamed ezzat m. mansour view author publications search author on: pubmed google scholar khalid radwan alsaadany view author publications search author on: pubmed google scholar mohamed awad e. ahmed view author publications search author on: pubmed google scholar ahmed ezzat elmetwalli view author publications search author on: pubmed google scholar corresponding author correspondence to mohamed ezzat m. mansour . ethics declarations competing of interest the authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper. additional information publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. supplementary information below is the link to the electronic supplementary material. esm 1 (docx 2.50 mb) rights and permissions springer nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. reprints and permissions about this article cite this article mansour, m.e.m., alsaadany, k.r., ahmed, m.a.e. et al. safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications. psychopharmacology 242 , 45–62 (2025). https://doi.org/10.1007/s00213-024-06723-5 download citation received : 18 september 2024 accepted : 22 november 2024 published : 19 december 2024 issue date : january 2025 doi : https://doi.org/10.1007/s00213-024-06723-5 share this article anyone you share the following link with will be able to read this content: get shareable link sorry, a shareable link is not currently available for this article. copy shareable link to clipboard provided by the springer nature sharedit content-sharing initiative keywords attention deficit/hyperactivity adhd dasotraline dopamine norepinephrine access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['mpu1'] = { 'pos': 'mpu1', 'type': 'mpu1', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; search search by keyword or author search navigation find a journal publish with us track your research discover content journals a-z books a-z publish with us journal finder publish your research language editing open access publishing products and services our products librarians societies partners and advertisers our brands springer nature portfolio bmc palgrave macmillan apress discover your privacy choices/manage cookies your us state privacy rights accessibility statement terms and conditions privacy policy help and support legal notice cancel contracts here 54.203.101.43 not affiliated © 2025 springer nature## Methods
a computer literature search (pubmed, scopus, web of science, and cochrane central) was conducted. we included rcts comparing dasotraline versus placebo. the primary outcome measure was the adhd rating scale-iv score, pooled as the mean difference between the two groups from baseline to the endpoint. the secondary outcome measures were the adhd rating scale-iv inattention score, adhd rating scale-iv hyperactivity score. results five rcts with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (md –2.65, 95% ci [–4.14 to –1.17], p= 0.0004 conclusion the results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed. this is a preview of subscription content, log in via an institution to check access. access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } fig. 1 fig. 2 fig. 3 fig. 4 fig. 5 fig. 6 fig. 7 similar content being viewed by others nonstimulant medications for attention-deficit/hyperactivity disorder (adhd) in adults: systematic review and meta-analysis article 11 may 2023 pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults article open access 23 november 2015 efficacy of pharmacological interventions for adhd: protocol for an updated systematic review and dose–response network meta-analysis article open access 12 october 2024 window.datalayer = window.datalayer || []; window.datalayer.push({ recommendations: { recommender: 'semantic', model: 'specter', policy_id: 'na', timestamp: 1761044428, embedded_user: 'null' } }); explore related subjects discover the latest articles, books and news in related subjects, suggested using machine learning. adhd attention deficit disorder drug therapy drug screening parkinson's disease therapeutics references sapkale b, sawal a (2023) attention deficit hyperactivity disorder (adhd) causes and diagnosis in adults: a review. cureus 15(11):e49144 pubmed pubmed central google scholar vold jh, halmøy a, chalabianloo f, pierron mc, løberg e-m, johansson ka et al (2023) attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study. bmc psychiatry 23(1):479 article pubmed pubmed central cas google scholar scandurra v, emberti gialloreti l, barbanera f, scordo mr, pierini a, canitano r (2019) neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (asd) and/or attention deficit and hyperactivity disorder (adhd). front psychiatry 10:673 article pubmed pubmed central google scholar abdelnour e, jansen mo, gold ja (2022) adhd diagnostic trends: increased recognition or overdiagnosis? mo med 119(5):467–473 pubmed pubmed central google scholar li y, yan x, li q, li q, xu g, lu j et al (2023) prevalence and trends in diagnosed adhd among us children and adolescents, 2017–2022. jama netw open 6(10):e2336872 article pubmed pubmed central google scholar schein j, adler la, childress a, cloutier m, gagnon-sanschagrin p, davidson m et al (2022) economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the united states: a societal perspective. j med econ 25(1):193–205 article pubmed google scholar schein j, adler la, childress a, gagnon-sanschagrin p, davidson m, kinkead f et al (2022) economic burden of attention-deficit/hyperactivity disorder among adults in the united states: a societal perspective. j manag care spec pharm 28(2):168–179 pubmed google scholar balazs j, kereszteny a (2017) attention-deficit/hyperactivity disorder and suicide: a systematic review. world j psychiatry 7(1):44–59 article pubmed pubmed central google scholar kosheleff ar, mason o, jain r, koch j, rubin j (2023) functional impairments associated with adhd in adulthood and the impact of pharmacological treatment. j atten disord 27(7):669–697 article pubmed pubmed central google scholar adamou m, arif m, asherson p, aw t-c, bolea b, coghill d et al (2013) occupational issues of adults with adhd. bmc psychiatry 13:59 article pubmed pubmed central google scholar sharma a, couture j (2014) a review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (adhd). ann pharmacother 48(2):209–225 article pubmed google scholar saboory e, ghasemi m, mehranfard n (2020) norepinephrine, neurodevelopment and behavior. neurochem int 135:104706 article pubmed cas google scholar klein mo, battagello ds, cardoso ar, hauser dn, bittencourt jc, correa rg (2019) dopamine: functions, signaling, and association with neurological diseases. cell mol neurobiol 39(1):31–59 article pubmed google scholar functional roles of norepinephrine and dopamine in adhd [internet]. [cited 2024 apr 9]. https://www.medscape.org/viewarticle/523887 curatolo p, d’agati e, moavero r. the neurobiological basis of adhd. italian journal of pediatrics [internet]. 2010;36(1):79. available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3016271/ ‌ pliszka sr, mccracken jt, maas jw (1996) catecholamines in attention-deficit hyperactivity disorder: current perspectives. j am acad child adolesc psychiatry 35(3):264–272 article pubmed cas google scholar faraone sv (2018) the pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. neurosci biobehav rev 87:255–270 article pubmed pubmed central cas google scholar reddy ds (2013) current pharmacotherapy of attention deficit hyperactivity disorder. drugs today 49(10):647–665 article cas google scholar verghese c, abdijadid s (2023) methylphenidate [internet]. nih.gov. statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk482451/ ‌ martin d, le jk (2023) amphetamine [internet]. pubmed. treasure island (fl): statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk556103/ ‌ delorenzo c, lichenstein s, schaefer k, dunn j, marshall r, organisak l et al (2011) sep-225289 serotonin and dopamine transporter occupancy: a pet study. j nucl med 52(7):1150–1155 article pubmed google scholar schreiber r, campbell u, quinton ms, hardy lw, fang qk, lew r (2022) in vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. biomed pharmacother 153:113359 article pubmed cas google scholar hopkins sc, sunkaraneni s, skende e, hing j, passarell ja, loebel a et al (2016) pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. clin drug investig 36(2):137–146 article pubmed cas google scholar chen y-l, skende e, lin j, yi y, wang pl, wills s et al (2017) absorption, distribution, metabolism, and excretion of [14 c]-dasotraline in humans. pharmacol res perspect 5(1):e00281 article pubmed google scholar wigal s, tsai j, bates ja, sarma k, tortorich d, zhu h et al (2022) a randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with adhd. j atten disord 26(10):1357–1368 article pubmed google scholar findling rl, adler la, spencer tj, goldman r, hopkins sc, koblan ks et al (2019) dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. j child adolesc psychopharmacol 29(2):80–89 article pubmed cas google scholar koblan ks, hopkins sc, sarma k, jin f, goldman r, kollins sh et al (2015) dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. neuropsychopharmacology 40(12):2745–2752 article pubmed pubmed central cas google scholar mcelroy sl, hudson ji, grilo cm, guerdjikova ai, deng l, koblan ks et al (2020) efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. j clin psychiatry 81(5) halevy-yosef r, bachar e, shalev l, pollak y, enoch-levy a, gur e et al (2019) the complexity of the interaction between binge-eating and attention. plos one 14(4):e0215506 article pubmed pubmed central cas google scholar page m, mckenzie j, bossuyt p, boutron i, hoffmann t, mulrow cd et al (2021) the prisma 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71 article pubmed pubmed central google scholar cochrane handbook for systematic reviews of interventions | cochrane training [internet]. [cited 2024 apr 10]. https://training.cochrane.org/handbook/current rayyan – intelligent systematic review - rayyan [internet]. [cited 2024 apr 10]. https://www.rayyan.ai/ higgins jpt, altman dg, gøtzsche pc, jüni p, moher d, oxman ad et al (2011) the cochrane collaboration’s tool for assessing risk of bias in randomised trials. bmj 343:d5928 article pubmed pubmed central google scholar döpfner m, steinhausen h-c, coghill d, dalsgaard s, poole l, ralston sj et al (2006) cross-cultural reliability and validity of adhd assessed by the adhd rating scale in a pan-european study. eur child adolesc psychiatry 15(suppl 1):i46–55 article pubmed google scholar busner j, targum sd (2007) the clinical global impressions scale: applying a research tool in clinical practice. psychiatry (edgmont) 4(7):28–37 pubmed google scholar wigal sb, gupta s, guinta d, swanson jm (1998) reliability and validity of the skamp rating scale in a laboratory school setting. psychopharmacol bull 34(1):47–53 pubmed cas google scholar murray dw, bussing r, fernandez m, wei hou, garvan cw, swanson jm et al (2009) psychometric properties of teacher skamp ratings from a community sample. assessment 16(2):193–208 article pubmed google scholar wigal sb, wigal t, schuck s, brams m, williamson d, armstrong rb et al (2011) academic, behavioral, and cognitive effects of oros ® methylphenidate on older children with attention-deficit/hyperactivity disorder. j child adolesc psychopharmacol 21(2):121–131 article pubmed pubmed central cas google scholar altman dg, bland jm (2005) standard deviations and standard errors. bmj 331(7521):903 article pubmed pubmed central google scholar egger m, smith g, schneider m, minder c (1997) bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629–634 article pubmed pubmed central cas google scholar grade handbook [internet] [cited 2024 apr 10]. https://gdt.gradepro.org/app/handbook/handbook.html wigal sb, hopkins sc, koblan ks, childress a, kent jm, tsai j et al (2020) efficacy and safety of dasotraline in children with adhd: a laboratory classroom study. j atten disord 24(2):192–204 article pubmed google scholar adler la, goldman r, hopkins sc, koblan ks, kent j, hsu j et al (2021) dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. int clin psychopharmacol 36(3):117–125 article pubmed google scholar peasgood t, bhardwaj a, biggs k, brazier je, coghill d, cooper cl et al (2016) the impact of adhd on the health and well-being of adhd children and their siblings. eur child adolesc psychiatry 25(11):1217–1231 article pubmed pubmed central google scholar download references author information authors and affiliations faculty of medicine, zagazig university, zagazig, egypt mohamed ezzat m. mansour medical research group of egypt, negida academy, arlington, ma, usa mohamed ezzat m. mansour, khalid radwan alsaadany, mohamed awad e. ahmed & ahmed ezzat elmetwalli faculty of medicine, mansoura university, mansoura, egypt khalid radwan alsaadany faculty of medicine, suez university, suez, egypt mohamed awad e. ahmed faculty of medicine, misr university for science and technology, giza, egypt ahmed ezzat elmetwalli authors mohamed ezzat m. mansour view author publications search author on: pubmed google scholar khalid radwan alsaadany view author publications search author on: pubmed google scholar mohamed awad e. ahmed view author publications search author on: pubmed google scholar ahmed ezzat elmetwalli view author publications search author on: pubmed google scholar corresponding author correspondence to mohamed ezzat m. mansour . ethics declarations competing of interest the authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper. additional information publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. supplementary information below is the link to the electronic supplementary material. esm 1 (docx 2.50 mb) rights and permissions springer nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. reprints and permissions about this article cite this article mansour, m.e.m., alsaadany, k.r., ahmed, m.a.e. et al. safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications. psychopharmacology 242 , 45–62 (2025). https://doi.org/10.1007/s00213-024-06723-5 download citation received : 18 september 2024 accepted : 22 november 2024 published : 19 december 2024 issue date : january 2025 doi : https://doi.org/10.1007/s00213-024-06723-5 share this article anyone you share the following link with will be able to read this content: get shareable link sorry, a shareable link is not currently available for this article. copy shareable link to clipboard provided by the springer nature sharedit content-sharing initiative keywords attention deficit/hyperactivity adhd dasotraline dopamine norepinephrine access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['mpu1'] = { 'pos': 'mpu1', 'type': 'mpu1', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; search search by keyword or author search navigation find a journal publish with us track your research discover content journals a-z books a-z publish with us journal finder publish your research language editing open access publishing products and services our products librarians societies partners and advertisers our brands springer nature portfolio bmc palgrave macmillan apress discover your privacy choices/manage cookies your us state privacy rights accessibility statement terms and conditions privacy policy help and support legal notice cancel contracts here 54.203.101.43 not affiliated © 2025 springer nature## Results
showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed.","datepublished":"2024-12-19t00:00:00z","datemodified":"2024-12-19t00:00:00z","pagestart":"45","pageend":"62","sameas":"https://doi.org/10.1007/s00213-024-06723-5","keywords":["attention deficit/hyperactivity","adhd","dasotraline","dopamine","norepinephrine","neurosciences","pharmacology/toxicology","psychiatry"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig1_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig2_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig3_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig4_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig5_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig6_html.png","https://media.springernature.com/lw1200/springer-static/image/art%3a10.1007%2fs00213-024-06723-5/mediaobjects/213_2024_6723_fig7_html.png"],"ispartof":{"name":"psychopharmacology","issn":["1432-2072","0033-3158"],"volumenumber":"242","@type":["periodical","publicationvolume"]},"publisher":{"name":"springer berlin heidelberg","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"imageobject"},"@type":"organization"},"author":[{"name":"mohamed ezzat m. mansour","url":"http://orcid.org/0009-0002-2195-2353","affiliation":[{"name":"zagazig university","address":{"name":"faculty of medicine, zagazig university, zagazig, egypt","@type":"postaladdress"},"@type":"organization"},{"name":"negida academy","address":{"name":"medical research group of egypt, negida academy, arlington, usa","@type":"postaladdress"},"@type":"organization"}],"email":"dr.mohammed.ezzat.mansour@gmail.com","@type":"person"},{"name":"khalid radwan alsaadany","affiliation":[{"name":"negida academy","address":{"name":"medical research group of egypt, negida academy, arlington, usa","@type":"postaladdress"},"@type":"organization"},{"name":"mansoura university","address":{"name":"faculty of medicine, mansoura university, mansoura, egypt","@type":"postaladdress"},"@type":"organization"}],"@type":"person"},{"name":"mohamed awad e. ahmed","affiliation":[{"name":"negida academy","address":{"name":"medical research group of egypt, negida academy, arlington, usa","@type":"postaladdress"},"@type":"organization"},{"name":"suez university","address":{"name":"faculty of medicine, suez university, suez, egypt","@type":"postaladdress"},"@type":"organization"}],"@type":"person"},{"name":"ahmed ezzat elmetwalli","affiliation":[{"name":"negida academy","address":{"name":"medical research group of egypt, negida academy, arlington, usa","@type":"postaladdress"},"@type":"organization"},{"name":"misr university for science and technology","address":{"name":"faculty of medicine, misr university for science and technology, giza, egypt","@type":"postaladdress"},"@type":"organization"}],"@type":"person"}],"isaccessibleforfree":false,"haspart":{"isaccessibleforfree":false,"cssselector":".main-content","@type":"webpageelement"},"@type":"scholarlyarticle"},"@context":"https://schema.org","@type":"webpage"} skip to main content advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['lb1'] = { 'pos': 'top', 'type': 'top', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; log in menu find a journal publish with us track your research search cart (function () { var exports = {}; if (window.fetch) { "use strict"; object.defineproperty(exports, "__esmodule", { value: true }); exports.headerwidgetclientinit = void 0; var headerwidgetclientinit = function (getcartinfo) { document.body.addeventlistener("updatedcart", function () { updatecarticon(); }, false); return updatecarticon(); function updatecarticon() { return getcartinfo() .then(function (res) { return res.json(); }) .then(refreshcartstate) .catch(function (_) { }); } function refreshcartstate(json) { var indicator = document.queryselector("#ecommerce-header-cart-icon-link .cart-info"); /* istanbul ignore else */ if (indicator && json.itemcount) { indicator.style.display = 'block'; indicator.textcontent = json.itemcount > 9 ? '9+' : json.itemcount.tostring(); var morethanoneitem = json.itemcount > 1; indicator.setattribute('title', "there ".concat(morethanoneitem ? "are" : "is", " ").concat(json.itemcount, " item").concat(morethanoneitem ? "s" : "", " in your cart")); } return json; } }; exports.headerwidgetclientinit = headerwidgetclientinit; headerwidgetclientinit( function () { return window.fetch("https://cart.springer.com/cart-info", { credentials: "include", headers: { accept: "application/json" } }) } ) }})() home psychopharmacology article safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications review published: 19 december 2024 volume 242 , pages 45–62, ( 2025 ) cite this article psychopharmacology aims and scope submit manuscript mohamed ezzat m. mansour orcid: orcid.org/0009-0002-2195-2353 1 , 2 , khalid radwan alsaadany 2 , 3 , mohamed awad e. ahmed 2 , 4 & … ahmed ezzat elmetwalli 2 , 5 show authors 412 accesses 4 altmetric explore all metrics abstract introduction attention-deficit/hyperactivity disorder (adhd) is a complex neurodevelopmental disorder. it is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. this study aimed to create evidence from published randomized clinical trials (rcts) about the benefits of dasotraline for adhd patients. methods a computer literature search (pubmed, scopus, web of science, and cochrane central) was conducted. we included rcts comparing dasotraline versus placebo. the primary outcome measure was the adhd rating scale-iv score, pooled as the mean difference between the two groups from baseline to the endpoint. the secondary outcome measures were the adhd rating scale-iv inattention score, adhd rating scale-iv hyperactivity score. results five rcts with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (md –2.65, 95% ci [–4.14 to –1.17], p= 0.0004 conclusion the results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed. this is a preview of subscription content, log in via an institution to check access. access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } fig. 1 fig. 2 fig. 3 fig. 4 fig. 5 fig. 6 fig. 7 similar content being viewed by others nonstimulant medications for attention-deficit/hyperactivity disorder (adhd) in adults: systematic review and meta-analysis article 11 may 2023 pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults article open access 23 november 2015 efficacy of pharmacological interventions for adhd: protocol for an updated systematic review and dose–response network meta-analysis article open access 12 october 2024 window.datalayer = window.datalayer || []; window.datalayer.push({ recommendations: { recommender: 'semantic', model: 'specter', policy_id: 'na', timestamp: 1761044428, embedded_user: 'null' } }); explore related subjects discover the latest articles, books and news in related subjects, suggested using machine learning. adhd attention deficit disorder drug therapy drug screening parkinson's disease therapeutics references sapkale b, sawal a (2023) attention deficit hyperactivity disorder (adhd) causes and diagnosis in adults: a review. cureus 15(11):e49144 pubmed pubmed central google scholar vold jh, halmøy a, chalabianloo f, pierron mc, løberg e-m, johansson ka et al (2023) attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study. bmc psychiatry 23(1):479 article pubmed pubmed central cas google scholar scandurra v, emberti gialloreti l, barbanera f, scordo mr, pierini a, canitano r (2019) neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (asd) and/or attention deficit and hyperactivity disorder (adhd). front psychiatry 10:673 article pubmed pubmed central google scholar abdelnour e, jansen mo, gold ja (2022) adhd diagnostic trends: increased recognition or overdiagnosis? mo med 119(5):467–473 pubmed pubmed central google scholar li y, yan x, li q, li q, xu g, lu j et al (2023) prevalence and trends in diagnosed adhd among us children and adolescents, 2017–2022. jama netw open 6(10):e2336872 article pubmed pubmed central google scholar schein j, adler la, childress a, cloutier m, gagnon-sanschagrin p, davidson m et al (2022) economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the united states: a societal perspective. j med econ 25(1):193–205 article pubmed google scholar schein j, adler la, childress a, gagnon-sanschagrin p, davidson m, kinkead f et al (2022) economic burden of attention-deficit/hyperactivity disorder among adults in the united states: a societal perspective. j manag care spec pharm 28(2):168–179 pubmed google scholar balazs j, kereszteny a (2017) attention-deficit/hyperactivity disorder and suicide: a systematic review. world j psychiatry 7(1):44–59 article pubmed pubmed central google scholar kosheleff ar, mason o, jain r, koch j, rubin j (2023) functional impairments associated with adhd in adulthood and the impact of pharmacological treatment. j atten disord 27(7):669–697 article pubmed pubmed central google scholar adamou m, arif m, asherson p, aw t-c, bolea b, coghill d et al (2013) occupational issues of adults with adhd. bmc psychiatry 13:59 article pubmed pubmed central google scholar sharma a, couture j (2014) a review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (adhd). ann pharmacother 48(2):209–225 article pubmed google scholar saboory e, ghasemi m, mehranfard n (2020) norepinephrine, neurodevelopment and behavior. neurochem int 135:104706 article pubmed cas google scholar klein mo, battagello ds, cardoso ar, hauser dn, bittencourt jc, correa rg (2019) dopamine: functions, signaling, and association with neurological diseases. cell mol neurobiol 39(1):31–59 article pubmed google scholar functional roles of norepinephrine and dopamine in adhd [internet]. [cited 2024 apr 9]. https://www.medscape.org/viewarticle/523887 curatolo p, d’agati e, moavero r. the neurobiological basis of adhd. italian journal of pediatrics [internet]. 2010;36(1):79. available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3016271/ ‌ pliszka sr, mccracken jt, maas jw (1996) catecholamines in attention-deficit hyperactivity disorder: current perspectives. j am acad child adolesc psychiatry 35(3):264–272 article pubmed cas google scholar faraone sv (2018) the pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. neurosci biobehav rev 87:255–270 article pubmed pubmed central cas google scholar reddy ds (2013) current pharmacotherapy of attention deficit hyperactivity disorder. drugs today 49(10):647–665 article cas google scholar verghese c, abdijadid s (2023) methylphenidate [internet]. nih.gov. statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk482451/ ‌ martin d, le jk (2023) amphetamine [internet]. pubmed. treasure island (fl): statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk556103/ ‌ delorenzo c, lichenstein s, schaefer k, dunn j, marshall r, organisak l et al (2011) sep-225289 serotonin and dopamine transporter occupancy: a pet study. j nucl med 52(7):1150–1155 article pubmed google scholar schreiber r, campbell u, quinton ms, hardy lw, fang qk, lew r (2022) in vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. biomed pharmacother 153:113359 article pubmed cas google scholar hopkins sc, sunkaraneni s, skende e, hing j, passarell ja, loebel a et al (2016) pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. clin drug investig 36(2):137–146 article pubmed cas google scholar chen y-l, skende e, lin j, yi y, wang pl, wills s et al (2017) absorption, distribution, metabolism, and excretion of [14 c]-dasotraline in humans. pharmacol res perspect 5(1):e00281 article pubmed google scholar wigal s, tsai j, bates ja, sarma k, tortorich d, zhu h et al (2022) a randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with adhd. j atten disord 26(10):1357–1368 article pubmed google scholar findling rl, adler la, spencer tj, goldman r, hopkins sc, koblan ks et al (2019) dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. j child adolesc psychopharmacol 29(2):80–89 article pubmed cas google scholar koblan ks, hopkins sc, sarma k, jin f, goldman r, kollins sh et al (2015) dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. neuropsychopharmacology 40(12):2745–2752 article pubmed pubmed central cas google scholar mcelroy sl, hudson ji, grilo cm, guerdjikova ai, deng l, koblan ks et al (2020) efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. j clin psychiatry 81(5) halevy-yosef r, bachar e, shalev l, pollak y, enoch-levy a, gur e et al (2019) the complexity of the interaction between binge-eating and attention. plos one 14(4):e0215506 article pubmed pubmed central cas google scholar page m, mckenzie j, bossuyt p, boutron i, hoffmann t, mulrow cd et al (2021) the prisma 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71 article pubmed pubmed central google scholar cochrane handbook for systematic reviews of interventions | cochrane training [internet]. [cited 2024 apr 10]. https://training.cochrane.org/handbook/current rayyan – intelligent systematic review - rayyan [internet]. [cited 2024 apr 10]. https://www.rayyan.ai/ higgins jpt, altman dg, gøtzsche pc, jüni p, moher d, oxman ad et al (2011) the cochrane collaboration’s tool for assessing risk of bias in randomised trials. bmj 343:d5928 article pubmed pubmed central google scholar döpfner m, steinhausen h-c, coghill d, dalsgaard s, poole l, ralston sj et al (2006) cross-cultural reliability and validity of adhd assessed by the adhd rating scale in a pan-european study. eur child adolesc psychiatry 15(suppl 1):i46–55 article pubmed google scholar busner j, targum sd (2007) the clinical global impressions scale: applying a research tool in clinical practice. psychiatry (edgmont) 4(7):28–37 pubmed google scholar wigal sb, gupta s, guinta d, swanson jm (1998) reliability and validity of the skamp rating scale in a laboratory school setting. psychopharmacol bull 34(1):47–53 pubmed cas google scholar murray dw, bussing r, fernandez m, wei hou, garvan cw, swanson jm et al (2009) psychometric properties of teacher skamp ratings from a community sample. assessment 16(2):193–208 article pubmed google scholar wigal sb, wigal t, schuck s, brams m, williamson d, armstrong rb et al (2011) academic, behavioral, and cognitive effects of oros ® methylphenidate on older children with attention-deficit/hyperactivity disorder. j child adolesc psychopharmacol 21(2):121–131 article pubmed pubmed central cas google scholar altman dg, bland jm (2005) standard deviations and standard errors. bmj 331(7521):903 article pubmed pubmed central google scholar egger m, smith g, schneider m, minder c (1997) bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629–634 article pubmed pubmed central cas google scholar grade handbook [internet] [cited 2024 apr 10]. https://gdt.gradepro.org/app/handbook/handbook.html wigal sb, hopkins sc, koblan ks, childress a, kent jm, tsai j et al (2020) efficacy and safety of dasotraline in children with adhd: a laboratory classroom study. j atten disord 24(2):192–204 article pubmed google scholar adler la, goldman r, hopkins sc, koblan ks, kent j, hsu j et al (2021) dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. int clin psychopharmacol 36(3):117–125 article pubmed google scholar peasgood t, bhardwaj a, biggs k, brazier je, coghill d, cooper cl et al (2016) the impact of adhd on the health and well-being of adhd children and their siblings. eur child adolesc psychiatry 25(11):1217–1231 article pubmed pubmed central google scholar download references author information authors and affiliations faculty of medicine, zagazig university, zagazig, egypt mohamed ezzat m. mansour medical research group of egypt, negida academy, arlington, ma, usa mohamed ezzat m. mansour, khalid radwan alsaadany, mohamed awad e. ahmed & ahmed ezzat elmetwalli faculty of medicine, mansoura university, mansoura, egypt khalid radwan alsaadany faculty of medicine, suez university, suez, egypt mohamed awad e. ahmed faculty of medicine, misr university for science and technology, giza, egypt ahmed ezzat elmetwalli authors mohamed ezzat m. mansour view author publications search author on: pubmed google scholar khalid radwan alsaadany view author publications search author on: pubmed google scholar mohamed awad e. ahmed view author publications search author on: pubmed google scholar ahmed ezzat elmetwalli view author publications search author on: pubmed google scholar corresponding author correspondence to mohamed ezzat m. mansour . ethics declarations competing of interest the authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper. additional information publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. supplementary information below is the link to the electronic supplementary material. esm 1 (docx 2.50 mb) rights and permissions springer nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. reprints and permissions about this article cite this article mansour, m.e.m., alsaadany, k.r., ahmed, m.a.e. et al. safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications. psychopharmacology 242 , 45–62 (2025). https://doi.org/10.1007/s00213-024-06723-5 download citation received : 18 september 2024 accepted : 22 november 2024 published : 19 december 2024 issue date : january 2025 doi : https://doi.org/10.1007/s00213-024-06723-5 share this article anyone you share the following link with will be able to read this content: get shareable link sorry, a shareable link is not currently available for this article. copy shareable link to clipboard provided by the springer nature sharedit content-sharing initiative keywords attention deficit/hyperactivity adhd dasotraline dopamine norepinephrine access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['mpu1'] = { 'pos': 'mpu1', 'type': 'mpu1', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; search search by keyword or author search navigation find a journal publish with us track your research discover content journals a-z books a-z publish with us journal finder publish your research language editing open access publishing products and services our products librarians societies partners and advertisers our brands springer nature portfolio bmc palgrave macmillan apress discover your privacy choices/manage cookies your us state privacy rights accessibility statement terms and conditions privacy policy help and support legal notice cancel contracts here 54.203.101.43 not affiliated © 2025 springer nature## Discussion
the results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for adhd symptoms. however, mild to moderate side effects were observed. this is a preview of subscription content, log in via an institution to check access. access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } fig. 1 fig. 2 fig. 3 fig. 4 fig. 5 fig. 6 fig. 7 similar content being viewed by others nonstimulant medications for attention-deficit/hyperactivity disorder (adhd) in adults: systematic review and meta-analysis article 11 may 2023 pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults article open access 23 november 2015 efficacy of pharmacological interventions for adhd: protocol for an updated systematic review and dose–response network meta-analysis article open access 12 october 2024 window.datalayer = window.datalayer || []; window.datalayer.push({ recommendations: { recommender: 'semantic', model: 'specter', policy_id: 'na', timestamp: 1761044428, embedded_user: 'null' } }); explore related subjects discover the latest articles, books and news in related subjects, suggested using machine learning. adhd attention deficit disorder drug therapy drug screening parkinson's disease therapeutics references sapkale b, sawal a (2023) attention deficit hyperactivity disorder (adhd) causes and diagnosis in adults: a review. cureus 15(11):e49144 pubmed pubmed central google scholar vold jh, halmøy a, chalabianloo f, pierron mc, løberg e-m, johansson ka et al (2023) attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study. bmc psychiatry 23(1):479 article pubmed pubmed central cas google scholar scandurra v, emberti gialloreti l, barbanera f, scordo mr, pierini a, canitano r (2019) neurodevelopmental disorders and adaptive functions: a study of children with autism spectrum disorders (asd) and/or attention deficit and hyperactivity disorder (adhd). front psychiatry 10:673 article pubmed pubmed central google scholar abdelnour e, jansen mo, gold ja (2022) adhd diagnostic trends: increased recognition or overdiagnosis? mo med 119(5):467–473 pubmed pubmed central google scholar li y, yan x, li q, li q, xu g, lu j et al (2023) prevalence and trends in diagnosed adhd among us children and adolescents, 2017–2022. jama netw open 6(10):e2336872 article pubmed pubmed central google scholar schein j, adler la, childress a, cloutier m, gagnon-sanschagrin p, davidson m et al (2022) economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the united states: a societal perspective. j med econ 25(1):193–205 article pubmed google scholar schein j, adler la, childress a, gagnon-sanschagrin p, davidson m, kinkead f et al (2022) economic burden of attention-deficit/hyperactivity disorder among adults in the united states: a societal perspective. j manag care spec pharm 28(2):168–179 pubmed google scholar balazs j, kereszteny a (2017) attention-deficit/hyperactivity disorder and suicide: a systematic review. world j psychiatry 7(1):44–59 article pubmed pubmed central google scholar kosheleff ar, mason o, jain r, koch j, rubin j (2023) functional impairments associated with adhd in adulthood and the impact of pharmacological treatment. j atten disord 27(7):669–697 article pubmed pubmed central google scholar adamou m, arif m, asherson p, aw t-c, bolea b, coghill d et al (2013) occupational issues of adults with adhd. bmc psychiatry 13:59 article pubmed pubmed central google scholar sharma a, couture j (2014) a review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (adhd). ann pharmacother 48(2):209–225 article pubmed google scholar saboory e, ghasemi m, mehranfard n (2020) norepinephrine, neurodevelopment and behavior. neurochem int 135:104706 article pubmed cas google scholar klein mo, battagello ds, cardoso ar, hauser dn, bittencourt jc, correa rg (2019) dopamine: functions, signaling, and association with neurological diseases. cell mol neurobiol 39(1):31–59 article pubmed google scholar functional roles of norepinephrine and dopamine in adhd [internet]. [cited 2024 apr 9]. https://www.medscape.org/viewarticle/523887 curatolo p, d’agati e, moavero r. the neurobiological basis of adhd. italian journal of pediatrics [internet]. 2010;36(1):79. available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3016271/ ‌ pliszka sr, mccracken jt, maas jw (1996) catecholamines in attention-deficit hyperactivity disorder: current perspectives. j am acad child adolesc psychiatry 35(3):264–272 article pubmed cas google scholar faraone sv (2018) the pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. neurosci biobehav rev 87:255–270 article pubmed pubmed central cas google scholar reddy ds (2013) current pharmacotherapy of attention deficit hyperactivity disorder. drugs today 49(10):647–665 article cas google scholar verghese c, abdijadid s (2023) methylphenidate [internet]. nih.gov. statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk482451/ ‌ martin d, le jk (2023) amphetamine [internet]. pubmed. treasure island (fl): statpearls publishing. available from: https://www.ncbi.nlm.nih.gov/books/nbk556103/ ‌ delorenzo c, lichenstein s, schaefer k, dunn j, marshall r, organisak l et al (2011) sep-225289 serotonin and dopamine transporter occupancy: a pet study. j nucl med 52(7):1150–1155 article pubmed google scholar schreiber r, campbell u, quinton ms, hardy lw, fang qk, lew r (2022) in vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. biomed pharmacother 153:113359 article pubmed cas google scholar hopkins sc, sunkaraneni s, skende e, hing j, passarell ja, loebel a et al (2016) pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. clin drug investig 36(2):137–146 article pubmed cas google scholar chen y-l, skende e, lin j, yi y, wang pl, wills s et al (2017) absorption, distribution, metabolism, and excretion of [14 c]-dasotraline in humans. pharmacol res perspect 5(1):e00281 article pubmed google scholar wigal s, tsai j, bates ja, sarma k, tortorich d, zhu h et al (2022) a randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with adhd. j atten disord 26(10):1357–1368 article pubmed google scholar findling rl, adler la, spencer tj, goldman r, hopkins sc, koblan ks et al (2019) dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. j child adolesc psychopharmacol 29(2):80–89 article pubmed cas google scholar koblan ks, hopkins sc, sarma k, jin f, goldman r, kollins sh et al (2015) dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. neuropsychopharmacology 40(12):2745–2752 article pubmed pubmed central cas google scholar mcelroy sl, hudson ji, grilo cm, guerdjikova ai, deng l, koblan ks et al (2020) efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. j clin psychiatry 81(5) halevy-yosef r, bachar e, shalev l, pollak y, enoch-levy a, gur e et al (2019) the complexity of the interaction between binge-eating and attention. plos one 14(4):e0215506 article pubmed pubmed central cas google scholar page m, mckenzie j, bossuyt p, boutron i, hoffmann t, mulrow cd et al (2021) the prisma 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71 article pubmed pubmed central google scholar cochrane handbook for systematic reviews of interventions | cochrane training [internet]. [cited 2024 apr 10]. https://training.cochrane.org/handbook/current rayyan – intelligent systematic review - rayyan [internet]. [cited 2024 apr 10]. https://www.rayyan.ai/ higgins jpt, altman dg, gøtzsche pc, jüni p, moher d, oxman ad et al (2011) the cochrane collaboration’s tool for assessing risk of bias in randomised trials. bmj 343:d5928 article pubmed pubmed central google scholar döpfner m, steinhausen h-c, coghill d, dalsgaard s, poole l, ralston sj et al (2006) cross-cultural reliability and validity of adhd assessed by the adhd rating scale in a pan-european study. eur child adolesc psychiatry 15(suppl 1):i46–55 article pubmed google scholar busner j, targum sd (2007) the clinical global impressions scale: applying a research tool in clinical practice. psychiatry (edgmont) 4(7):28–37 pubmed google scholar wigal sb, gupta s, guinta d, swanson jm (1998) reliability and validity of the skamp rating scale in a laboratory school setting. psychopharmacol bull 34(1):47–53 pubmed cas google scholar murray dw, bussing r, fernandez m, wei hou, garvan cw, swanson jm et al (2009) psychometric properties of teacher skamp ratings from a community sample. assessment 16(2):193–208 article pubmed google scholar wigal sb, wigal t, schuck s, brams m, williamson d, armstrong rb et al (2011) academic, behavioral, and cognitive effects of oros ® methylphenidate on older children with attention-deficit/hyperactivity disorder. j child adolesc psychopharmacol 21(2):121–131 article pubmed pubmed central cas google scholar altman dg, bland jm (2005) standard deviations and standard errors. bmj 331(7521):903 article pubmed pubmed central google scholar egger m, smith g, schneider m, minder c (1997) bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629–634 article pubmed pubmed central cas google scholar grade handbook [internet] [cited 2024 apr 10]. https://gdt.gradepro.org/app/handbook/handbook.html wigal sb, hopkins sc, koblan ks, childress a, kent jm, tsai j et al (2020) efficacy and safety of dasotraline in children with adhd: a laboratory classroom study. j atten disord 24(2):192–204 article pubmed google scholar adler la, goldman r, hopkins sc, koblan ks, kent j, hsu j et al (2021) dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. int clin psychopharmacol 36(3):117–125 article pubmed google scholar peasgood t, bhardwaj a, biggs k, brazier je, coghill d, cooper cl et al (2016) the impact of adhd on the health and well-being of adhd children and their siblings. eur child adolesc psychiatry 25(11):1217–1231 article pubmed pubmed central google scholar download references author information authors and affiliations faculty of medicine, zagazig university, zagazig, egypt mohamed ezzat m. mansour medical research group of egypt, negida academy, arlington, ma, usa mohamed ezzat m. mansour, khalid radwan alsaadany, mohamed awad e. ahmed & ahmed ezzat elmetwalli faculty of medicine, mansoura university, mansoura, egypt khalid radwan alsaadany faculty of medicine, suez university, suez, egypt mohamed awad e. ahmed faculty of medicine, misr university for science and technology, giza, egypt ahmed ezzat elmetwalli authors mohamed ezzat m. mansour view author publications search author on: pubmed google scholar khalid radwan alsaadany view author publications search author on: pubmed google scholar mohamed awad e. ahmed view author publications search author on: pubmed google scholar ahmed ezzat elmetwalli view author publications search author on: pubmed google scholar corresponding author correspondence to mohamed ezzat m. mansour . ethics declarations competing of interest the authors declare that there exists no competing financial interest or personal relationships that could have appeared to influence the work reported in this paper. additional information publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. supplementary information below is the link to the electronic supplementary material. esm 1 (docx 2.50 mb) rights and permissions springer nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. reprints and permissions about this article cite this article mansour, m.e.m., alsaadany, k.r., ahmed, m.a.e. et al. safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications. psychopharmacology 242 , 45–62 (2025). https://doi.org/10.1007/s00213-024-06723-5 download citation received : 18 september 2024 accepted : 22 november 2024 published : 19 december 2024 issue date : january 2025 doi : https://doi.org/10.1007/s00213-024-06723-5 share this article anyone you share the following link with will be able to read this content: get shareable link sorry, a shareable link is not currently available for this article. copy shareable link to clipboard provided by the springer nature sharedit content-sharing initiative keywords attention deficit/hyperactivity adhd dasotraline dopamine norepinephrine access this article log in via an institution subscribe and save springer+ from $39.99 /month starting from 10 chapters or articles per month access and download chapters and articles from more than 300k books and 2,500 journals cancel anytime view plans buy now buy article pdf usd 39.95 price excludes vat (usa) tax calculation will be finalised during checkout. instant access to the full article pdf. datalayer.push({"ecommerce":{"currency":"usd","impressions":[{"name":"safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including grade qualifications","id":"1432-2072","price":39.95,"brand":"springer berlin heidelberg","category":"neuroscience","variant":"ppv-article","quantity":1}]}}); ;(function () { if (window.localstorage) { window.localstorage.removeitem("springerplusrollout") } })() .springer-plus .buying-option-usps > li::before { background-image: url("data:image/svg+xml,%3csvg viewbox='0 0 100 100' xmlns='http://www.w3.org/2000/svg' fill='%230070a8'%3e%3ccircle cx='50' cy='50' r='50'/%3e%3c/svg%3e"); } institutional subscriptions .sprcom-buybox-articledarwin .buybox__access-option{ border-top: 1px solid #cedbe0; font-size: 1rem; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus{ background-color: #ebf6ff; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; padding: 16px; } .sprcom-buybox-articledarwin .springer-plus-headline{ display: flex; justify-content: space-between; } .sprcom-buybox-articledarwin .springer-plus-heading{ border-bottom: 1px solid #c5e0f4; border-top: 1px solid #c5e0f4; font-family: 'merriweather sans', 'helvetica neue', helvetica, arial, sans-serif; font-size: 1.125rem; font-weight: 700; margin: 0; padding: 16px; text-align: center; } .sprcom-buybox-articledarwin .springer-plus-title{ align-items: center; display: flex; } .sprcom-buybox-articledarwin .springer-plus-title span{ margin-left: 8px; } .sprcom-buybox-articledarwin .springer-plus a{ background-color: #fff; border: 1px solid #025e8d; color: #025e8d; font-size: 16px; font-weight: 700; max-height: 44px; } .sprcom-buybox-articledarwin .springer-plus a span{ margin-right: 8px; } .sprcom-buybox-articledarwin .springer-plus a:hover{ background-color: #025e8d; border: 4px solid #025e8d; box-shadow: none; color: #fff; font-weight: 700; } .sprcom-buybox-articledarwin .springer-plus a:visited{ color: #025e8d; } .sprcom-buybox-articledarwin .springer-plus a:visited:hover{ color: #fff; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps{ color: #555; font-size: 1rem; line-height: 1.6; list-style: none; margin: 0; padding: 16px 0 24px 0; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li{ padding-left: 26px; position: relative; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li::before{ content: ''; height: 10px; left: 0; position: absolute; top: calc(0.8em - 5px); width: 10px; } .sprcom-buybox-articledarwin .springer-plus .buying-option-usps > li:not(:first-child){ margin-top: 4px; } advertisement window.sn = window.sn || {}; window.sn.libs = window.sn.libs || {}; window.sn.libs.ads = window.sn.libs.ads || {}; window.sn.libs.ads.slotconfig = window.sn.libs.ads.slotconfig || {}; window.sn.libs.ads.slotconfig['mpu1'] = { 'pos': 'mpu1', 'type': 'mpu1', }; window.sn.libs.ads.slotconfig['unitpath'] = '/270604982/springerlink/213/article'; search search by keyword or author search navigation find a journal publish with us track your research discover content journals a-z books a-z publish with us journal finder publish your research language editing open access publishing products and services our products librarians societies partners and advertisers our brands springer nature portfolio bmc palgrave macmillan apress discover your privacy choices/manage cookies your us state privacy rights accessibility statement terms and conditions privacy policy help and support legal notice cancel contracts here 54.203.101.43 not affiliated © 2025 springer nature## Scraping Notes- Successfully scraped from DOI.org